trending Market Intelligence /marketintelligence/en/news-insights/trending/zd3ixju3oze4vvch1wyhug2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Synthorx closes IPO

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity

COVID-19 Impact & Recovery: Corporates


Synthorx closes IPO

Synthorx Inc. closed its previously announced IPO of 13,699,636 common shares, priced at $11 each.

Shares sold include underwriters' full exercise of their option to buy 1,786,909 additional common shares, at the IPO price.

The La Jolla, Calif.-based company, which develops novel protein therapeutics for pain, infectious diseases, metabolic diseases and cancer, raised gross proceeds of $150.7 million.

Shares sold under the IPO started trading Dec. 7 on the Nasdaq Global Select Market under the symbol THOR.

Jefferies LLC, Leerink Partners LLC and Evercore ISI acted as joint book-running managers for the IPO, with H.C. Wainwright & Co. LLC as lead manager.

The company previously said net proceeds will be used to fund research and development of its IL-2 synthorins, which target cancer and autoimmune disorders, as well as other development programs, and for working capital and other general corporate purposes.